en, English


  • Short treatment times (5-15 minutes)
  • Probes in various sizes, for targeted iceball
  • Safe and efficient probe design
  • Liquid nitrogen for maximum efficacy
  • Convenient and easy to use system

The procedure is fast, easy and comfortable; it can be completed in minutes, in the physician’s office, under ultrasound guidance. With minimal impact on the patient’s routine, cryoablation has a short recovery time, and leaves virtually no scarring.

IceSense3™ Probe

  • Various sizes, designed for tailoring the size of the ablation zone
  • Efficiency and safety maximized
  • Heat exchange mechanism located at tip to confine iceball and freezing to targeted zone
  • Vacuum insulation along length of probe further protects tissue and skin outside targeted zone of treatment
  • Disposable component is small

IceSense3™ Console

  • Convenient touch screen to customize the procedure for the individual patient
  • Unit controlled from console touch screen and buttons, handle, or foot pedal
  • Cryoablation system utilizes liquid nitrogen for efficient freeze-thaw-freeze cycles

IceSense3™ Cryoablation is a Fast, Easy, Comfortable Procedure

  • Simple, ultrasound-guided procedure
  • Rapid cryoablation
  • Office-based cryoablation is comfortable for patients
  • Patients report high satisfaction from treatment and results
  • Effective, durable procedure for treating fibroadenomas

Why is IceSense3™ Cryoablation a Compelling Treatment Option?

  • Immediate, safe, effective and durable lesion ablation in the office
  • No breast tissue is removed
  • No sutures required (steri-strip procedure)
  • Cryoablation creates cosmetically superior results — no cavity for hematoma formation or volume loss


MIRAâ„¢ Technology

MIRA utilizes dual-head proprietary Structured Light Projection Infrared imaging technology to construct 3-D vascular maps of the breasts.

Blood vessels are an essential part of solid cancers as they supply oxygen and nutrients. New vessels are also formed during cancer progression, a process that can further allow cancer growth and expansion. Therefore, assessment of cancer vascularity might provide information to characterize underlying malignancy. In the past decade, several studies have demonstrated the association between breast cancer and vascularity using contrast-enhanced MRI.

The MIRA technology can assess breast vascularity for likelihood of malignancy. The assessment is based on sophisticated multi-desciplinary machine learning technology, that provides the physician a Risk Assessment Score. The Risk Assessment Score has been clinically validated in a population of women with histology confirmed breast cancer.


Biop Medical

Biop Medical has developed a revolutionary hybrid/modular device for cervical cancer screening and diagnosis.

The device is comprised of the following components:

  • Biop's control unit

  • Biop's Digital Colposcope unit

  • Biop's Micro Colposcope Probe unit with a single-use, disposable cover

  • Dedicated computer with a proprietary software

  • Dedicated tripod (optional)


The Device and its' Hybrid Operation

The Biop’s Micro- Colposcope Probe unit captures a macro-image of the cervix, using its macro-camera, before being brought to contact with the cervix. After contacting the cervix, the high-magnification camera scans the cervix and obtains high-resolution, high-magnification images within a radius of 11mm around the external os, which serves as the center of the scan.
This high-resolution data is then processed by a dedicated software that improves the image quality using common image enhancement methods, such as illumination field artifact removal and contrast enhancement.
The high-magnification images obtained by the probe unit are then registered with the panoramic images obtained by the Digital Colposcope unit (see registration details below). In addition, the high-magnification images are tiled into a single image of the entire scanned area, which s free of optical aberrations or tiling artifacts.



The EVA (Enhanced Visual Assessment) Colpo 3 Plus System is a powerful tool for visualizing the cervix and coordinating screening and treatment services for patients across all levels of care. The EVA 3 Plus offers an improved super-amoled 5.2-inch screen with 720×1280 HD resolution.  “EVA COLPO is one of the greatest things to happen to women’s cervical health. It allows clinicians to review cervix images after an examination and is also really helpful for patients to be shown part of their anatomy they don’t usually get an opportunity to visualize.”  – Bonnie Betts, Nurse Practitioner FPA Medical  EASY-TO-USE DEVICE – An FDA approved mobile colposcope equipped with a reliable light source and a powerful magnification lens for enhanced visualization. USER-FRIENDLY MOBILE APP – A HIPAA compliant application for patient image and data capture that enables remote consultation, patient tracking, and referral coordination. CLOUD BASED INFORMATION SYSTEM – The EVA Cloud provides secure, everywhere access, to real time data to monitor provider utilization cases reviewed, anonymized patient statistics, and intuitive tools to enhance quality control and quality improvement opportunities. HARDWARE FEATURESThe EVA System uses a mobile colposcope designed for durability and portability. Features include: Ultra-bright light source with cross-polarization to reduce glare Lens enabling up to 16X magnification for superior imaging Rechargeable, long-lasting battery for up to 10 hours of continuous use SOFTWARE FEATURES The EVA System runs on secure software to allow for real-time enhanced visualization of the cervix, empowering health providers to: Securely enter and review patient images and data Consult in real time or asynchronously with remote experts for decision support Counsel and educate patients using cervical images to improve engagement PORTAL FEATURES The EVA System strengthens all cervical cancer programs, including those using VIA, VILI, HPV, and/or Pap. All information and patient data are securely stored in the online EVA System portal, which is accessible by designated personnel. Program managers and clinical supervisors can: Review screening results and consultation decisions from anywhere in the world Access program level analytics for quality assurance and supportive supervision Integrate EVA System data with electronic medical records software via APIs The EVA System is being used to screen women globally, including sub-Saharan Africa, Central America, the Caribbean, Europe, India, and the United States.